- Home
- CASI vs ELTX Comparison
CASI vs ELTX Comparison
Compare CASI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- ELTX
- Stock Information
- Founded
- CASI 1991
- ELTX 2011
- Country
- CASI China
- ELTX United States
- Employees
- CASI N/A
- ELTX N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- ELTX Health Care
- Exchange
- CASI Nasdaq
- ELTX Nasdaq
- Market Cap
- CASI 58.8M
- ELTX 54.6M
- IPO Year
- CASI 1996
- ELTX 2021
- Fundamental
- Price
- CASI $2.36
- ELTX $9.11
- Analyst Decision
- CASI Strong Buy
- ELTX Strong Buy
- Analyst Count
- CASI 1
- ELTX 3
- Target Price
- CASI $6.00
- ELTX $9.50
- AVG Volume (30 Days)
- CASI 30.6K
- ELTX 42.1K
- Earning Date
- CASI 11-15-2024
- ELTX 11-13-2024
- Dividend Yield
- CASI N/A
- ELTX N/A
- EPS Growth
- CASI N/A
- ELTX N/A
- EPS
- CASI N/A
- ELTX N/A
- Revenue
- CASI $22,055,000.00
- ELTX N/A
- Revenue This Year
- CASI N/A
- ELTX N/A
- Revenue Next Year
- CASI $134.79
- ELTX N/A
- P/E Ratio
- CASI N/A
- ELTX N/A
- Revenue Growth
- CASI N/A
- ELTX N/A
- 52 Week Low
- CASI $2.05
- ELTX $2.96
- 52 Week High
- CASI $7.67
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- CASI 33.52
- ELTX 66.42
- Support Level
- CASI $2.27
- ELTX $6.20
- Resistance Level
- CASI $2.73
- ELTX $9.99
- Average True Range (ATR)
- CASI 0.24
- ELTX 0.55
- MACD
- CASI 0.02
- ELTX 0.26
- Stochastic Oscillator
- CASI 12.70
- ELTX 64.64
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.